Tositumomab and Iodine 131I Tositumomab

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names

North America

Canada: Bexxar; USA: Bexxar.

Drug combinations


Tositumomab: Immunoglobulin G~2a~ anti-(human antigen CD 20)(mouse monoclonal clone B1R1 γ2a-chain), disulfide with mouse monoclonal clone B1R1 λ~x~-chain, dimer. CAS-192391-48-3.

Pharmacologic Category

Other Antineoplastic Agents; Monoclonal Antibodies. (ATC-Code: V10XA53).

Mechanism of action

Tositumomab is a murine IgG~2a~ λ monoclonal antibody which binds to CD20 antigen, expressed on B-lymphocytes and on >90% of B-cell non-Hodgkin lymphomas. Administration results in depletion of CD20 positive cells.

Therapeutic use

Treatment of relapsed or refractory CD20 positive, low-grade, follicular, or transformed non-Hodgkin lymphoma.

Pregnancy and lactiation implications

Risk of fetal harm. Contraindicated in pregnancy and lactation.

Unlabeled use


Hypersensitivity to murine proteins or any component of the formulation. Pregnancy. Breast-feeding.

Warnings and precautions

Serious, including fatal, hypersensitivity reactions reported. Risk of severe thrombocytopenia and neutropenia. Do not use in >25% lymphoma marrow involvement and/or impaired bone marrow reserve.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart